World Journal of Gastrointestinal Surgery

World J Gastrointest Surg 2022 March 27; 14(3): 211-270





Published by Baishideng Publishing Group Inc

WJGS

World Journal of Gastrointestinal Surgery

Contents

Monthly Volume 14 Number 3 March 27, 2022

ORIGINAL ARTICLE

Case Control Study

Fast-track protocols in laparoscopic liver surgery: Applicability and correlation with difficulty scoring 211 systems

Ciria R, Padial A, Ayllón MD, García-Gaitan C, Briceño J

Does cranial-medial mixed dominant approach have a unique advantage for laparoscopic right 221 hemicolectomy with complete mesocolic excision?

Lin L, Yuan SB, Guo H

Retrospective Study

236 New common bile duct morphological subtypes: Risk predictors of common bile duct stone recurrence Ji X, Yang Z, Ma SR, Jia W, Zhao Q, Xu L, Kan Y, Cao Y, Wang Y, Fan BJ

META-ANALYSIS

247 Peroral endoscopic longer vs shorter esophageal myotomy for achalasia treatment: A systematic review and meta-analysis

Weng CY, He CH, Zhuang MY, Xu JL, Lyu B

CASE REPORT

Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for 260 hepatocellular carcinoma: A case report

Endo Y, Shimazu M, Sakuragawa T, Uchi Y, Edanami M, Sunamura K, Ozawa S, Chiba N, Kawachi S

LETTER TO THE EDITOR

Is it sufficient to evaluate only preoperative systemic inflammatory biomarkers to predict postoperative 268 complications after pancreaticoduodenectomy?

Demirli Atici S. Kamer E



Contents

Monthly Volume 14 Number 3 March 27, 2022

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Surgery, Vishal Gupta, FACS, MBBS, MCh, MS, Additional Professor, Surgeon, Department of Surgical Gastroenterology, All India Institute of Medical Sciences, Bhopal 462020, India. vggis@yahoo.co.in

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, and PubMed Central. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGS as 2.582; IF without journal self cites: 2.564; 5-year IF: 3.378; Journal Citation Indicator: 0.53; Ranking: 97 among 212 journals in surgery; Quartile category: Q2; Ranking: 73 among 92 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Gastrointestinal Surgery	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1948-9366 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
November 30, 2009	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Peter Schemmer	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-9366/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
March 27, 2022	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2022 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



S WÛ

World Journal of Gastrointestinal Surgery

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2022 March 27; 14(3): 247-259

DOI: 10.4240/wjgs.v14.i3.247

ISSN 1948-9366 (online)

META-ANALYSIS

Peroral endoscopic longer vs shorter esophageal myotomy for achalasia treatment: A systematic review and meta-analysis

Chun-Yan Weng, Cheng-Hai He, Ming-Yang Zhuang, Jing-Li Xu, Bin Lyu

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): C Grade D (Fair): D Grade E (Poor): 0

P-Reviewer: Beraldo RF, Cabezuelo AS, Oda M

Received: September 27, 2021 Peer-review started: September 27, 2021

First decision: December 4, 2021 Revised: December 9, 2021 Accepted: February 16, 2022 Article in press: February 16, 2022 Published online: March 27, 2022



Chun-Yan Weng, Department of Gastroenterology, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China

Cheng-Hai He, Department of Gastroenterology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310006, Zhejiang Province, China

Ming-Yang Zhuang, Internal Medicine of Chinese Medicine, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China

Jing-Li Xu, Department of Surgery, The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China

Bin Lyu, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou 310006, Zhejiang Province, China

Corresponding author: Bin Lyu, PhD, Professor, Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medicine University, No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. lvbin@medmail.com.cn

Abstract

BACKGROUND

Peroral endoscopic myotomy (POEM) has been demonstrated to be safe and effective in the treatment of achalasia. Longer myotomy is the standard POEM procedure for achalasia but when compared with shorter myotomy, its effectiveness is not as well known.

AIM

To compare the clinical effectiveness of longer and shorter myotomy.

METHODS

PubMed, EmBase, Cochrane Library, web of science and clinicaltrials.gov were queried for studies comparing shorter and longer POEM for achalasia treatment. The primary outcome was clinical success rate. Secondary outcomes comprised of operative time, adverse events (AEs) rate, gastroesophageal reflux disease (GERD) and procedure-related parameters. The Mantel-Haenszel fixed-effects model was primarily used for the analysis. Publication bias was assessed.

RESULTS

Six studies were included in this analysis with a total of 514 participants. During the follow-up period of 1-28.7 mo, longer and shorter myotomy in treating



WJGS https://www.wjgnet.com

achalasia showed similar excellent effectiveness [overall clinical success (OR = 1, 95%CI: 0.46-2.17, P = 1, I²: 0%; subgroup of abstract (OR = 1.19, 95%CI: 0.38 to 3.73; P = 0.76; I²: 0%); subgroup of full text (OR = 0.86 95%CI: 0.30 to 2.49; P = 0.78; I²: 0%)]. Shorter myotomy had significantly reduced mean operative time compared with the longer procedure. There were no statistically significant differences in AEs rates, including GERD (overall OR = 1.21, 95%CI: 0.76-1.91; P = 0.42; I²: 9%; subgroup of abstract OR = 0.77, 95%CI: 0.40-1.47; P = 0.43; I²: 0%; subgroup of full text OR = 1.91, 95%CI: 0.98-3.75; P = 0.06; I²: 0%), hospital stay (overall MD = -0.07, 95%CI: -0.30 to 0.16; P = 0.55; I²: 24%; subgroup of abstract MD = 0.20, 95%CI: -0.25 to 0.65; P = 0.39; I²: 0; subgroup of full text MD = -0.16, 95%CI: -0.42 to 0.10; P = 0.23; I²: 42%), and major bleeding (overall OR = 1.25, 95%CI: 0.58-2.71; P = 0.56; I²: 0%) between the two procedures. These differences remained statistically non-significant in all sensitivity analyses.

CONCLUSION

POEM was effective in treating achalasia. Shorter and longer myotomy procedures provided similar therapeutic effects in terms of long-term effectiveness. In addition, shorter myotomy reduced the operative time.

Key Words: Endoscopy; Meta-analysis; Myotomy; Peroral endoscopic myotomy; Gastroesophageal reflux disease

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We evaluated the peroral endoscopic longer *vs* shorter myotomy for achalasia treatment in our study. To our knowledge, this is the first meta-analysis aiming to compare longer and shorter myotomy during peroral endoscopic myotomy for the treatment of achalasia regarding clinical success, safety and procedure-related outcomes. Shorter and longer myotomy procedures showed similar therapeutic effects in terms of long-term effectiveness. In addition, shorter myotomy reduced the operative time.

Citation: Weng CY, He CH, Zhuang MY, Xu JL, Lyu B. Peroral endoscopic longer *vs* shorter esophageal myotomy for achalasia treatment: A systematic review and meta-analysis. *World J Gastrointest Surg* 2022; 14(3): 247-259 **URL:** https://www.wjgnet.com/1948-9366/full/v14/i3/247.htm **DOI:** https://dx.doi.org/10.4240/wjgs.v14.i3.247

INTRODUCTION

Achalasia is a rare esophageal motor disease with a prevalence of approximately 1 case/100000 adults. The pathophysiology of achalasia disorder involves incomplete relaxation of the lower esophageal sphincter (LES) and impaired esophageal peristalsis[1]. Its clinical manifestations comprise dysphagia, regurgitation, chest pain and weight loss. Currently, endoscopic botulinum toxin injection or pneumatic dilation and laparoscopic Heller myotomy (LHM) are used to treat achalasia[2]. Inoue and colleagues[3] carried out the first peroral endoscopic myotomy (POEM) surgery to treat 17 achalasia patients in 2010 with 100% technical success. POEM is a novel, minimally invasive therapeutic modality for achalasia and related disorders, which was first reported by Inoue *et al*[3] in 2010. Since then, POEM has been widely used in the treatment of achalasia in many studies and achieves excellent efficacy[4-7].

However, the technique of POEM has changed very little since its introduction[3]. During POEM, the variable extent of gastric myotomy and esophageal myotomy range from 2 cm to 3 cm and 6 cm to 10 cm, respectively. Meanwhile, previous studies have demonstrated the significance of the extent of the myotomy on the gastric side[8,9]. However, the clinical relevance of myotomy length on the esophagus remains unknown. Some researchers have also adopted shorter myotomy in POEM and achieved similar efficacy in recent years[10].

The existing literature lacks high-quality evidence to compare the clinical outcomes of short-length and long-length POEM for achalasia treatment. Furthermore, for shorter or longer myotomy in POEM, which is more effective remains unknown. In this study, we compared the two myotomy modalities based on clinical outcomes and the incidence of postoperative adverse events.

Raisbidena® WJGS | https://www.wjgnet.com

MATERIALS AND METHODS

Data source and search strategy

The present systematic review and meta-analysis was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, EmBase, Web of Science, Cochrane Library and clinicaltrials.gov databases were searched for relevant studies published from January 2010 to October 2020, because POEM was first reported in humans in 2010[3]. The searching language of publications was restricted to English. The Medical Subject Headings (MESH) terms employed included Achalasia's, Esophageal OR Esophageal Achalasia's OR Cardiospasm OR Cardiospasms OR Achalasia OR Achalasia's OR Achalasia, Esophageal OR Megaesophagus OR Esophageal Achalasia AND POEM OR Peroral endoscopic myotomy OR esophageal myotomy OR Peroral endoscopic myotomy AND shorter OR longer OR modified. The reference lists of eligible articles were further assessed for additional studies of interest. Two investigators independently performed the search and data extraction, assessed the quality of the articles and the discrepancies were resolved by consensual discussion. The third investigator reviewed the extracted data. Discussion with senior authors solved any arising issues. Randomized clinical trials (RCTs) and retrospective studies were qualified for the search.

Study selection

Article title and abstract eligibility screening was performed in an independent way by two investigators. Open-label double-blinded RCTs, as well as retrospective trials evaluating patients and comparing peroral endoscopic shorter and longer myotomy for the treatment of achalasia were included. Exclusion criteria were: (1) Experimental studies; (2) Publication language other than English; and (3) An editorial, a case report, a review or case series.

The data parameters obtained from each study were: (1) Trial features such as study design, sample size, follow-up duration and publication year; (2) Primary outcome, i.e. clinical success; and (3) Secondary outcomes, including (i) operative time, (ii) GERD (the main indicator was endoscopic reflux esophagitis), (iii) total number of adverse events (AEs) such as major bleeding, and (iv) procedurerelated parameters.

Quality assessment

The Cochrane "risk of bias" tool and the Newcastle-Ottawa Scale (NOS) were employed for assessing methodological quality of included studies[11]. Discrepancies between the two investigators were resolved by consensual discussion.

Statistical analysis

Review Manager 5.3 (RevMan) was utilized to analyze the extracted data and determine odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity was determined by inspection of forest plots, the Cochrane Q test, and the I² statistic. A Q test with P<0.10 was considered significant. According to the Cochrane Handbook for Systematic Reviews of Interventions (https://training.cochrane.org/ handbook), I² values were categorized as: < 30%, low heterogeneity; 30%-50%, moderate heterogeneity; > 50%, substantial heterogeneity; > 75%, high heterogeneity.

RESULTS

Patient baseline features

Details of the selection process were outlined in Figure 1. Overall, 711 articles were initially selected. After ruling out duplicates, reviews, case series, irrelevant and nonstandard records, 6 studies were included which involved 3RCTs and 3 retrospective trials[12-17] and covered 545 patients. Their features are summarized in Table 1. The quality assessment of the studies was depicted in Figure 2. No significant differences were found in age, sex, American Society of Anesthesiologists (ASA) classification and previous interventions[18]. The detailed study quality evaluation items were presented in Table 2. Compared with the long myotomy (LM) group, the length of esophageal myotomy in the short myotomy (SM) group was significantly reduced. The total incision range of the LM group was 8-25 cm, including 6-20 cm on the esophagus and 2-5 cm on the stomach. For the SM group, the cut range was 3-7cm, including 2-6 cm on the esophagus and 1-3 cm on the stomach.

Clinical success

All patients were followed up for clinical success rate and Eckardt score. Data on clinical success after POEM were available in six studies (Figure 3) [overall clinical success (OR = 1, 95% CI: $0.46-2.17, P = 1, I^2$: 0%; subgroup of abstract (OR = 1.19, 95% CI: 0.38 to 3.73; P = 0.76; I^2 : 0%); subgroup of full text (OR = 0.86 95% CI: 0.30 to 2.49; P = 0.78; I^2 : 0%)]. Therefore, clinical success of POEM showed no statistically significant difference between the two groups.



Table 1 Art	ticles' feat	ures							
Ref.	Total sample	Sex, male/female, n	Age, yr	Symptoms duration, yr or mo	МВІ	Classification, <i>n</i> (%)	Pre-ECK scores	LESP, mmHg	IRP, mmHg
Familiari <i>et</i> <i>al</i> [15], 2016	LM: 38	NA	NA	NA	NA	NA	NA	NA	NA
<i>u</i> [10], 2010	SM: 35								
Gao <i>et al</i> [<mark>16</mark>], 2017	LM: 53	LM: 29/24; SM: 25/22	LM: 37.83 ± 14.36	LM: 5.23 ± 5.87	LM: 19.76 ± 3.07	NA	LM: 6.75 ± 1.86	LM: 43.03 ± 13.73	NA
	SM: 47		SM: 43.96 ± 11.69	SM: 5.30 ± 4.87	SM: 20.25 ± 2.97		SM: 6.34 ± 1.74	SM: 41.93 ± 14.93	
Gong <i>et al</i> [17], 2016	LM: 59; SM: 38	Female; LM: 29; SM: 19	LM: 39.8 ± 12.4; SM: 41.5 ± 7.2	LM: 6.5 ± 5.5; SM: 7.9 ± 4.3	LM: 20.7 ± 2.6; SM: 20.1 ± 3.2	ASAC I: LM: 47; SM: 29; II: LM: 11; SM: 7; III: LM: 1; SM: 2; CC I: LM: 21; SM: 12 II: LM: 38; SM: 26	LM: 7.2 ± 2.4; SM: 6.8 ± 1.7	LM: 42.1 ± 12.9; SM: 44.6 ± 13.2	NA
Gu et al [<mark>14</mark>], 2020	LM: 48; SM: 46	LM: 23/25; SM: 21/25	LM: 42.8 ± 10.2; SM: 43.6 ± 11.4	LM: 4.1(0.3~31.0); SM: 5.0(0.3~34.0	NA	CC II: LM: 48; SM: 46	LM: 7.1 ± 1.6; SM: 7.5 ± 1.5	LM: 32.4 ± 5.3; SM: 33.5 ± 5.0	LM: 21.5 ± 4.6; SM: 23.2 ± 4.8
Huang <i>et al</i> [<mark>13</mark>], 2020	LM: 74; SM: 36	Female; LM: 34; SM: 17	LM: 37.7 ± 13.0; SM: 40.8 ± 11.1	LM: 8.9 ± 5.8; SM: 8.8 ± 5.5	LM: 19.4 ± 3.1; SM: 20.3 ± 2.6	ASAC I: LM: 58; SM: 33; II: LM: 15; SM: 2; III: LM: 1; SM: 1; CC I: LM: 26; SM: 12; II: LM: 48; SM: 24	LM: 7.5 ± 1.9; SM: 7.1 ±1.6	LM: 39.8 ± 13.7; SM: 41.8 ± 14.3	NA
Nabi <i>et al</i> [<mark>12</mark>],2020	LM: 37; SM: 34	LM: 24/13; SM: 18/16	LM: 41.3 ± 14.4; SM: 40.1 ± 16.8	LM: 3;SM: 3	NA	ASAC I: LM: 13; SM: 12; II: LM: 24; SM: 22	LM: 6.75 ± 1.32; SM: 6.02 ± 1.33	NA	LM: 28.50 ± 11.01; SM: 26.40 ± 13.9

Data are presented as mean ± standard deviation or n (%). ASAC: American Society of Anesthesiologists classification; BMI: Body mass index; CC: Chicago classification; IRP: Integrated relaxation pressure; LESP: Lower esophagus sphincter pressure; LM: Long myotomy; NA: Not Applied; Pre-ECK scores: Preoperative- peroral endoscopic myotomy Eckardt scores; SM: Short myotomy.

> Five studies presented pre-POEM Eckardt score as a quantitative variable. The score was 6.75 ± 1.86 , 7.2 ± 2.4 , 7.1 ± 1.6 , 7.5 ± 1.9 , 6.75 ± 1.32 in the LM group, respectively. In the SM group, the score was 6.34 ± 1.74 , 6.8 ± 1.7 , 7.5 ± 1.5 , 7.1 ± 1.6 and 6.02 ± 1.33 , respectively. Six studies provided postoperative Eckardt scores, which were also comparable between the LM and SM group. The postoperative Eckardt score in the LM group was 0.5 ± 0.8; 0.98 ± 1.14; 1.2 ± 1.2; 0.72 ± 0.42; 1.6 ± 1.3; 0.818 ± 0.983, respectively. Similarly, the score in the SM group was 0.5 ± 0.8 ; 1.06 ± 1.42 ; 1.0 ± 0.9 ; 0.76 ± 0.51 ; 1.3 ± 1.2 and 0.935 ± 0.935 0.929, respectively.

Procedure-related outcomes

Operative time: Total procedure duration was available in all six articles including a total of 521 patients. The operative time in the LM group was 59.2 ± 16.7 , 63.13 ± 26.50 , 68.5 ± 23.2 , 45.6 ± 16.2 , 62.1 ± 16.2 , 25.2 and 72.43 ± 27.28, respectively. For the SM group, the time was 47.7 ± 13.2, 50.62 ± 20.02, 44.2 ± 16.3, 31.2 ± 15.3 , 46.6 ± 18.5 and 44.03 ± 13.78 , respectively. Obviously, the operative times in the SM group were shorter than that in the LM group (Figure 4).

Length of myotomy: A total of 3 RCTs and 2 retrospective studies involving 421 cases were metaanalyzed, with 180 cases in the SM group and 241 cases in the LM group. Myotomy length in POEM included the span of esophageal and gastric myotomy. The total length of myotomy in the LM group was 11.10 ± 2.0 , 11.5 ± 3.1 and 11.7 ± 2.4 cm, respectively. Among them, the esophageal myotomy length was 8.42 ± 2.13 , 8.2 ± 2.7 , 10.14 ± 0.54 , 7.97 ± 2.40 and 8.5 ± 2.6 cm, respectively, and the gastromyotomy length was 2.49 ± 0.70 , 3.2 ± 1.4 , 3.2 ± 1.2 and 2.84 ± 0.63 cm, respectively. The following myotomy values were obtained in the SM group of six studies: total length in three studies, 6.04 ± 0.69 , 6.1 ± 0.5 and 6.0 ± 0.6 cm, respectively; esophageal length in five studies, 3.87 ± 0.61 , 4.0 ± 0.9 , 5.66 ± 0.14 , 4.0 ± 0.7 and 2.76 ± 0.41 cm, respectively; and gastric length in four studies, 2.21 ± 0.41 , 2.1 ± 0.3 , 3.2 ± 1.2 and 2.70 \pm 0.73 cm, respectively.

Manometry outcomes: Preoperative LES pressure in POEM was available in four articles with a total of 401 patients, and five articles including 450 individuals assessed postoperative LES pressure. The level of preoperative LES pressure in the LM group was 43.03 ± 13.73 , 42.1 ± 12.9 , 32.4 ± 5.3 and 39.8 ± 13.7 mmHg respectively, and the value was 41.93 ± 14.93 , 44.6 ± 13.2 , 33.5 ± 5.0 and 41.8 ± 14.3 mmHg,



WJGS | https://www.wjgnet.com

	uetalleu stu	dy quality evalua									
Ref.	Follow-up sample	Length of the myotomy, cm	Operative time, min	Myotomy length, cm	Follow-up time, mo	Clinical success	GERD, %	LESP, mmHg	HRM, mmHg	Post-ECK scores	Adverse events
Familiari et al[15] _, 2016	LM: 23 SM: 26	LM: 13 SM: 8	LM: 59.2 ± 16.7 SM: 47.7 ± 13.2	ES: LM: 8.42 ± 2.13 SM: 3.87 ± 0.61 ST: LM: 2.49 ± 0.70 SM: 2.21 ± 0.41 TO: LM: 10.94 ± 2.11 SM: 6.04 ± 0.69	8	LM: 100% SM: 100%	LM: 42.9% SM: 65%	LM: 17 ± 9.7 SM: 11.4 ± 6.5	LM: 8.6 ± 4.9 SM: 5.9 ± 5.0	LM: 0.5 ± 0.8 SM: 0.5 ± 0.8	No
Gao et al[<mark>16]</mark> , 2017	LM: 53 SM: 47	LM: > 7 SM: ≤7	LM: 63.13 ± 26.5 SM: 50.62 ± 20.02	NA	3,6,12	LM: 96.2% SM: 93.6%	LM: 11.3% SM: 12.8%	LM: 16.51 ± 5.01 SM: 17.41 ± 3.69	NA	LM: 0.98 ± 1.14 SM: 1.06 ± 1.42	MB: LM: 0, SM: 0 MP: LM: 1; SM: 0 HS: LM: 10.19 ± 4.03 SM: 10.21 ± 3.78
Gong <i>et al</i> [17] _, 2016	LM: 59 SM: 38	LM: > 7 SM: ≤7	LM: 68.5 ± 23.2 SM: 44.2 ± 16.3	ES: LM: 8.5 ± 2.6 SM: 4.0 ± 0.9 ST: LM: 3.2 ± 1.4 SM: 2.1+0.3 TO: LM: 11.7 ± 2.4 SM: 6.1 ± 0.5	NA	LM: 91.5% SM: 92.1%	LM: 18.6% SM: 15.8%	LM: 19.3 ± 8.5 SM: 16.7 ± 4.3	NA	LM: 1.2 ± 1.2 SM: 1.0 ± 0.9	MB: LM: 3; SM: 2 MP: LM: 1; SM: 0 HS: LM: 6.6 ± 1.1 SM: 6.4 ± 1.2
Gu et al[<mark>14</mark>] _, 2020	LM: 48 SM: 46	LM: 7-8 SM: 3-4	LM: 45.6 ± 16.2 SM: 31.2 ± 15.3	ES: LM: 10.14 ± 0.54 SM: 5.66 ± 0.14	1,3,6,12	LM: 93.8% SM: 95.7%	LM: 22.9% SM: 15.2%	LM: 12.1 ± 3.9 SM: 11.8 ± 4.4	LM: 9.7 ± 2.6 SM: 10.1 ± 2.4	LM: 0.72 ± 0.42 SM: 0.76 ± 0.51	HS: LM: 6: 5 ± 1.6 SM: 7.0 ± 0.9
Huang <i>et al</i> [<mark>13</mark>] _, 2020	LM: 74 SM: 36	LM > 7 SM≤ 7	LM: 62.1 ± 25.2 SM: 46.6 ± 18.5	ES: LM: 8.2 ± 2.7 SM: 4.0 ± 0.7 ST: LM: 3.2 ± 1.2 SM: 3.2 ± 1.2 TO: LM: 11.5 ± 3.1 SM: 6.0 ± 0.6	28.7	LM: 91.9% SM: 94.4%	LM: 14.9% SM: 8.3%	LM: 13.3 ± 5.7 SM: 15.9 ± 3.2	NA	LM: 1.6 ± 1.3 SM: 1.3 ± 1.2	MB: LM: 3; SM: 2 MP: LM: 1; SM: 0 HS: LM: 9.3 ± 2.9 SM: 9.9 ± 2.4
Nabi <i>et al</i> [<mark>12</mark>], 2020	LM: 37 SM: 34	LM: ≥ 6 SM: ≤ 3	LM: 72.43 ± 27.28 SM: 44.03 ± 13.78	ES: LM: 7.97 ± 2.40 SM: 2.76 ± 0.41 ST: LM: 2.84 ± 0.63 SM: 2.70 ± 0.73	12	LM: 96.97% SM: 93.55%	LM: 56.67%SM: 44.4%	NA	LM: 7.44 ± 4.30 SM: 8.60 ± 1.30	LM: 0.818 ± 0.983 SM: 0.935 ± 0.929	MB: LM: 17; SM: 12 HS: LM: 2.81 ± 0.70 SM: 2.82 ± 0.67


Table 2 The detailed study quality evaluation items

Data are presented as mean ± standard deviation or *n* (%). Eck: Eckardt score; ES: Esophageal; HS: Hospitalization, mean days; MB: Major bleeding; MP: Mucosal perforation; Post-ECK scores: Postoperative- peroral endoscopic myotomy; CERD: Gastroesophageal reflux disease; LM: Long myotomy; NA: Not Applied; SM: Short myotomy; ST: Stomach; TO: Total.

respectively, in the SM group. Postoperative LES pressure level in the LM group was 17 ± 9.7 , 16.51 ± 5.01 , 19.3 ± 8.5 , 12.1 ± 3.9 and 13.3 ± 5.7 mmHg, respectively, and the pressure level was 11.4 ± 6.5 , 17.41 ± 3.69 , 16.7 ± 4.3 , 11.8 ± 4.4 and 15.9 ± 3.2 mmHg, respectively, in the SM group.

Integrated relaxation pressure: Preoperative integrated relaxation pressure (IRP) in POEM was available in two articles with a total of 165 patients, and three articles including 214 individuals assessed postoperative IRP pressure. The levels of preoperative IRP in the LM group were 21.5 ± 4.6 mmHg and 28.50 ± 11.01 mmHg, and in the SM group, the values were 23.2 ± 4.8 mmHg and 26.40 ± 13.9 mmHg. Postoperative IRP level in the LM group was 8.6 ± 4.9 , 9.7 ± 2.6 , and 7.44 ± 4.30 mmHg, respectively, and this pressure level was 5.9 ± 5.0 , 10.1 ± 2.4 and 8.60 ± 1.30 mmHg, respectively, in the SM group.

Endoscopic reflux esophagitis: This meta-analysis found no difference in endoscopic reflux esophagitis between the two procedures (total OR = 1.21, 95%CI: 0.76-1.91; P = 0.42; I²: 9%; subgroup of abstract OR = 0.77, 95%CI: 0.40-1.47; P = 0.43; I²: 0%; subgroup of full text OR = 1.91, 95%CI: 0.98-3.75; P = 0.06; I²: 0%), with low heterogeneity found. Hence, random- and fixed-effects models yielded identical results (Figure 5A).



DOI: 10.4240/wjgs.v14.i3.247 Copyright The Author(s) 2022.

Figure 1 Flow diagram of the study selection process.




Figure 2 Risk of bias of the enrolled studies. The methodological quality of the included studies was similar. No study had a high risk for confounding variables.


AEs: The incidence rates of AEs in different studies are detailed in Table 2. No procedure-related deaths were recorded. The rate of hospitalization showed no difference between the two procedures (total MD = -0.07, 95% CI: -0.30 to 0.16; P = 0.55; I²: 24%; subgroup of abstract MD = 0.20, 95% CI: -0.25 to 0.65; P = 0.39; I²: 0; subgroup of full text MD = -0.16, 95% CI: -0.42 to 0.10; P = 0.23; I²: 42%), with no heterogeneity detected (Figure 5B). The incidence rate of major bleeding was similar comparing the two groups (total OR = 1.25, 95% CI: 0.58-2.71; P = 0.56; I²: 0%) (Figure 5C). These differences remained statistically significant in all sensitivity analyses.

DISCUSSION

In this meta-analysis, we critically assessed the available RCTs and retrospective studies comparing SM and LM during POEM for the treatment of achalasia. Our main findings were that both approaches



WJGS https://www.wjgnet.com



DOI: 10.4240/wjgs.v14.i3.247 Copyright The Author(s) 2022.

Figure 3 Long vs short myotomy. Meta-analysis of primary outcomes (clinical success rate).

were equally effective yet the shorter procedure required reduced operation time. Heterogeneity across the studies was low and a comprehensive sensitivity analysis was consistent with our primary findings. No publication bias was detected.

The notion of endoscopic myotomy was first put forward by Ortega and collaborators[19], with an electrosurgical knife utilized for dissecting the lower esophageal rosette without manipulating the distal anti-reflux zone. Nevertheless, direct endoscopic myotomy has serious complications, and it has been abandoned. POEM was first reported by Pasricha and collaborators[20] in 2007 with pigs and utilized a submucosal tunnel for LES myotomy. In 2010, Inoue and collaborators[3] first applied POEM clinically using seven individuals who received a relatively shorter myotomy (mean length of 4.9 cm and 1.0 cm on the gastric side) but had worse clinical outcomes compared with the 10 cases undergoing a longer myotomy (mean length of 10.4 cm). With regard to myotomy length in POEM, Inoue and colleagues recommended to use a length of > 10 cm (average 13 cm) as the standard[21]. Since then, POEM has been considered as an emerging treatment modality and is the preferred therapeutic option for achalasia and has shown success in all age groups and different types and stages of achalasia[22]. In addition, POEM is promising in the treatment for spastic esophageal motility ailments. Avoiding abdominal incisions could reduce surgical invasiveness, improve cosmetic effects and shorten convalescence time [23]. Moreover, POEM has been widely used clinically due to its advantages over LHM[24] including no abdominal cut, faster recovery and the possibility of avoiding general anesthesia. In addition, unlike LHM, POEM does not involve GEJ dissection[25].

The major differences in the implementation of POEM worldwide include myotomy orientation (anterior or posterior), thickness (full or partial) and length (shorter and longer). With regard to myotomy length in POEM surgery, Von Renteln and colleagues (Germany), Costamagna and collaborators (Italy), Chiu and co-workers (Hong Kong, China) and Minami and colleagues (Japan), all performed LM to treat achalasia with a mean incision length of 12, 10, 10.8 or 14.4 cm, and promising efficacy and safety have been achieved[26-29]. However, these trials adopted the original LM POEM technique by Inoue *et al*[21], with a myotomy length of about 10 cm. Meanwhile, the average LES length was only 3.2 cm, ranging from 2.4 to 4.0 cm in healthy and achalasia individuals[30]. According to the



$1.1 \text{ Altered} \\ Familiari et al 2016 Abstract. 23 23 25 26 Not estimable \\ Gong et al 2016 Abstract. 54 59 35 38 28.20% 0.33 [0.21, 4.12] \\ Subtract (SYRC1) 135 111 42.0% 1.19 [0.38, 3.73] \\ Total events 128 105 \\ Heterogenerity : Ch2 = 0.27, df = 1 (P = 0.60); f2 = 0% \\ Tack for ward effect : 2 = 0.30 (P = 0.76) \\ 12 full text \\ Gui et al 2020 46 74 34 35 22.0% 0.46 [0.11, 4.28] \\ Heterogenerity : Ch2 = 0.27, df = 1 (P = 0.60); f2 = 0% \\ Tack for ward effect : 2 = 0.30 (P = 0.76) \\ 12 full text \\ Gui et al 2020 46 74 34 35 22.0% 0.46 [0.11, 4.28] \\ Heterogenerity : Ch2 = 0.7, df = 2 (P = 0.76) \\ Tack for ward effect : 2 = 0.30 (P = 0.76) \\ Tack for ward effect : 2 = 0.30 (P = 0.76) \\ Tack for ward effect : 2 = 0.30 (P = 0.76) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 1.08) ; f2 = 0% \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.30 (P = 0.78) \\ Tack for ward effect : 2 = 0.31 2 25 3 202 47 13.20% 1150 [10.0, 20.00] \\ 21 Abstract \\ Tack for ward effect : 2 = 6.71 (P < 0.0001) \\ 22 full text \\ Gui et al 2020 45.6 16.2 48 31.2 15.3 46 27.10% 114.40 [8.03, 20.77] \\ Tack for wareal effect : 2 = 7.61 (P < 0.0001) \\ 22 full text \\ Gui et al 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] \\ Subtract [95%C1) 15 111 40.06% 15.50 [7.52 ; 3.88] \\ Abstract 2020 45.6 16.2 49 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] \\ Fack for wareal effect : 2 = 7.61 (P < 0.0001) \\ 22 full text \\ Gui et al 2020 45.6 16.2 49 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] \\ Fack for wareal effect : 2 = 7.65 (P < 0.0001) \\ Tack for wareal effect : 2 = 7$	Study or Subgroup	Events	Total	Events	Total	Weight			lds Ratio Fixed, 95%Cl		Odds Ratio M-H, Fixed, 95%	6Cl	
See of al 2017 Abstract. 51 53 44 47 13.80% $1.74 [0.28, 10.88]$ Gong af 2016 Abstract. 54 59 35 38 28.20% $0.93 [0.21, 41.2]$ Subtrat (95%C) 135 111 42.0% $0.93 [0.21, 41.2]$ Table control 128 105 Historoganaly: $0.0^{+} = 0.27, df = 1 (P = 0.63); J^{2} = 0\%$ Tash for ownall effect : $Z = 0.30 (P = 0.76)$ 12 full tast Gai eff 2020 45 45 46 44 46 22.0% $0.68 [0.11, 4.28]$ Historoganaly: $0.0^{+} = 0.27, df = 1 (P = 0.63); J^{2} = 0\%$ Tash for ownall effect : $Z = 0.30 (P = 0.76)$ Table control 155 113 58.0% $0.68 [0.11, 4.28]$ Historoganaly: $0.0^{+} = 0.27, df = 2 (P = 0.70); J^{2} = 0\%$ Tash for ownall effect : $Z = 0.20 (P = 0.73)$ Table control 155 113 58.0% $0.68 [0.11, 4.28]$ Historoganaly: $0.0^{+} = 0.27, df = 2 (P = 0.70); J^{2} = 0\%$ Tash for ownall effect : $Z = 0.20 (P = 0.73)$ Table control 1.15 $0.0 (0.46, 2.17)$ Historoganaly: $0.0^{+} = 0.27, df = 2 (P = 0.73); J^{2} = 0\%$ Table control 1.15 $0.0 (0.46, 2.17)$ Table control 1.15 $0.0 (0.46, 0.17)$ Table control 1.15 $0.0 (0.000)$ Table control 1.15 $0.0 $	1.1 Abstract												
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Familiari <i>et al</i> . 2016 Abstract.	23	23	26	26				Not estimable				
Subtral (95%C1) 135 111 42.0% 1.19 [0.38, 3.73] Total events 128 105 Heargeoraeity: $Oh = 0.27$, $d^2 = 1 (P = 0.60)$; $P = 0.95$ Tat for overall effect : $2 = 0.30$ ($P = 0.76$); $P = 0.95$ Tat for overall effect : $2 = 0.30$ ($P = 0.76$); $P = 0.95$ Tat for overall effect : $2 = 0.30$ ($P = 0.76$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.26$ ($P = 0.70$); $P = 0.95$ Tat for overall effect : $2 = 0.06$ ($P = 1.00$) Tat for subgroup Mean 50 Total Mean 50 Total Weight Musc States ($P = 0.85$); $P = 0.95$ Tat for overall effect : $2 = 0.06$ ($P = 1.00$) Tat for subgroup Mean 50 Total Mean 50 Total Weight Musc States ($P = 0.85$); $P = 0.95$ Tat for overall effect : $2 = 0.53$, $d = 2$ ($P = 0.05$); $P = 0.95$ Tat for overall effect : $2 = 0.53$, $d = 2$ ($P = 0.05$); $P = 0.95$ Tat for overall effect : $2 = 0.53$, $d = 2$ ($P = 0.05$); $P = 0.95$ Tat for overall effect : $2 = 0.53$, $d = 2$ ($P = 0.05$); $P = 0.95$ Tat for overall effect : $2 = 0.53$, $d = 2$ ($P = 0.05$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.71$ ($P < 0.050$); $P = 0.95$ Tat for overall effect : $2 = 0.72$, $d = 2.72$ ($P = 0.05$); $P = 0.95$ Tat effect overall	Gao <i>et al</i> . 2017 Abstract.	51	53	44	47	13.80%		1.74	[0.28, 10.88]			•	
Total events 128 105 Heterogeneity: $Ch^{2} = 0.27$, $d^{2} = 1$ ($P = 0.60$); $I^{2} = 0\%$ Test for overall effect: $Z = 0.30$ ($P = 0.76$) 1.2 Full test Gui et al. 2020 45 48 44 46 22.0% 0.66 [0.11, 4.28] Heterogeneity: $Ch^{2} = 0.72$, $d^{2} = 2$ ($P = 0.76$) 1.2 Full test Gui et al. 2020 32 33 29 31 7.10% 2.21 [0.19, 25.64] Total events 145 107 Heterogeneity: $Ch^{2} = 0.72$, $d^{2} = 2$ ($P = 0.78$); $I^{2} = 0\%$ Total events 145 107 Heterogeneity: $Ch^{2} = 0.72$, $d^{2} = 2$ ($P = 0.78$); $I^{2} = 0\%$ Total events 273 212 Total events 200 ($P = 1.07$); $I^{2} = 0\%$ Total events 200 ($P = 1.07$); $I^{2} = 0\%$ Total events 200 ($P = 1.07$); $I^{2} = 0\%$ Total events 200 ($P = 1.07$); $I^{2} = 0\%$ Total events 2017. $d = 1$ ($P = 0.68$); $I^{2} = 0\%$ Total events 2010 ($P = 1.07$); $I^{2} = 0\%$ Total events 2010 ($P = 1.07$); $I^{2} = 0\%$ Total events 2010 ($P = 1.07$) Test for subgroup differences; $Ch^{2} = 0.17$, $d = 1$ ($P = 0.68$); $I^{2} = 0\%$ Subtroat (2017 Abstract 63.13 265 53 50.62 20.02 47 13.10\% 12.51 [3.36, 21.66] Gorg et al. 2016 Abstract 65.5 23.2 59 44.2 16.3 38 [7.70\% 24.30 [16.43, 32.17] Subtroat [2016 Abstract 63.13 26.5 53 50.62 20.02 47 13.10\% 12.51 [3.36, 21.66] Gorg et al. 2016 Abstract 65.5 23.2 59 44.2 16.3 38 [7.70\% 24.30 [16.43, 32.17] Subtroat [2016 Abstract 63.13 26.5 53 50.62 20.02 47 13.10\% 12.51 [3.36, 21.66] Gorg et al. 2016 Abstract 65.5 23.2 59 44.2 16.3 38 [7.70\% 24.30 [16.43, 32.17] Total ($P = -5.55$, $d = 2$ ($P = 0.05$); $I^{2} = 6\%$ Test for overall effect; $Z = -6.71$ ($P < 0.00001$) Total ($P = -5.75$, $d = 2$ ($P = 0.05$); $I^{2} = 6\%$ Test for overall effect; $Z = -7.5$ ($P = 0.0001$) Total ($P > 0.2$ 20.72 43 27.28 37 44.03 13.78 34 11.10\% 24.64 [18.45, 38.4] Heterogeneity: $Ch^{2} = 5.75$, $d = 2$ ($P = 0.05$); $I^{2} = 65\%$ Test for overall effect; $Z = 7.55$ ($P < 0.00001$	Gong <i>et al.</i> 2016 Abstract.	54	59	35	38	28.20%		0.93	8 [0.21, 4.12]				_
Heterogenety: Ch ² = 0.27, df = 1 ($P = 0.60$); $I^2 = 0.95$ Test for overall effect: Z = 0.30 ($P = 0.76$); 1.2 Full text Gu et al 2020 45 48 44 46 22.0% 0.68 [0.11, 4.28] 1.2 Full text Gu et al 2020 68 74 33 29 31 7.10% 2.21 [0.19, 254] Skotch (95%C1) 155 113 58.0% 0.86 [0.30, 2.49] 5 Constant 45 107 Heterogenety: Ch ² = 0.28 ($P = 0.70$); $I = 0\%$ Test for overall effect: Z = 0.28 ($P = 0.70$); $I = 0\%$ Test for overall effect: Z = 0.08 ($P = 0.78$); $I = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, df = 1 ($P = 0.68$); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.05); $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.05); $I^2 = 0\%$ Test for overall effect : Z = 0.00 ($P = 0.05$); $I^2 = 0\%$ Test for overall effect : Z = 0.67 ($P = 0.05$); $I^2 = 0\%$ Test for overall effect : Z = 0.17 ($P = 0.00001$) Test for overall effect : Z = 6.71 ($P < 0.00001$) Test for overall effect : Z = 6.71 ($P < 0.00001$) Test for overall effect : Z = 6.71 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect : Z = 7.75 ($P < 0.00001$) Test for overall effect	Subtotal(95%Cl)		135		111	42.0%		1.19	9 [0.38, 3.73]				
Text for overall effect : $Z = 0.30$ ($P = 0.76$) 1.2 Full text (2 or ad 2020 45 48 44 46 22.0% 0.68 [0.11, 4.28] the er ad 2020 52 33 29 31 7.10% 2.21 [0.19, 25.4] Soluble (d 2020 12 32 33 29 31 7.10% 2.21 [0.19, 25.4] Soluble (d 2020 12 32 37 212 Total events 15 107 Total events 145 107 Total events 273 212 Text for overall effect : $Z = 0.28$ ($P = 0.70$); $P = 0\%$ Text for overall effect : $Z = 0.28$ ($P = 0.70$); $P = 0\%$ Text for overall effect : $Z = 0.00$ ($P = 1.09$) Text for subgroup $Mean$ SD Total $Mean$ SD Total $Mean$ $Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean SD Total Mean Dffuence Newly or Subgroup Mean SD Total Mean Df N, Fixed, 95%CI N, $	Total events	128		105									
$12 \ Full text Gu et al. 2020 12 \ Full text Gu et al. 2020 12 \ Full text Gu et al. 2020 12 \ Full text 13 \ Full text 13 \ Full text 14 \ Full text 15 \$	Heterogeneity : Chi² = 0.27 , o	df = 1 (<i>P</i> =	0.60); I ²	= 0%									
Su et al. (2020) 45 48 44 46 22.0% $0.68 [0.11, 4.28]$ Hung et al. (2020) 68 74 34 36 29.0% $0.67 [0.13, 3.48]$ 0.67 [0.13, 3.48] Total events 145 107 Total events 145 107 Total events 145 107 Total events 273 212 Heterogeneity: Ch ² = 0.78 ($P = 0.78$) Total events 273 212 Heterogeneity: Ch ² = 0.16, $df = 2 (P = 0.70)$; $I^2 = 0\%$ Test for overall effect: $Z = 0.28 (P = 0.78)$ Total events 273 212 Heterogeneity: Ch ² = 0.16, $df = 4 (P = 0.88)$; $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for overall effect: $Z = 0.01 (P = 1.00)$ Test for subgroup differences : Ch ² = 0.17, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for overall effect: $Z = 0.017$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for overall effect: $Z = 0.017$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for overall effect: $Z = 0.017$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Test for overall effect: $Z = 0.017$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Total events $II, 0.010, 0.0200$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0\%$ Test for overall effect: $Z = 0.05 $, $I^2 = 0\%$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0\%$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0\%$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0\%$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0\%$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0.05$ Test for overall effect: $Z = 0.17, P = 0.05$, $I^2 = 0.05$ Test for overall effect: $Z = 0.78, P = 0.05$, $I^2 = 0.05$ Test for overall effect: $Z = 0.78, P = 0.05$, $I^2 = 0.05$ Test for overall effect: $Z = 0.78, P = 0.05$, $I^2 = 0.05$ Test for overall effect: $Z = 0.78, P = 0.05$, $I^2 = 0.05$ Test for over	Test for overall effect : $Z = 0.3$	30 (<i>P</i> = 0.76)										
Hung et al. 2020 68 74 34 36 29.0% 0.67 [$0.13, 3.48$] Nalai et al. 2020 32 33 29 31 7.10% 2.21 [$0.15, 25.64$] Subtotal (95%Cl) 155 113 58.0% 0.86 [$0.30, 2.49$] 0.86 [$0.30, 2.49$] Total events 145 107 Heterogeneity: Chi ² = 0.72, df = 2 ($P = 0.70$); $I^2 = 0\%$ $1.00 [0.46, 2.17]$ Total events 273 212 Heterogeneity: Chi ² = 1.16, df = 4 ($P = 0.88$); $I^2 = 0\%$ Test for overall effect: $Z = 0.00$ ($P = 1.00$) Test for subgroup Mean So Total Subtotal (95%Cl) 20.2 1.4 Motract Subgroup Mean So Total Mean So Total So So Total So Total Mean So So Total Mean So Total Mean So Total Mean So So Total	1.2 Full text												
Neble at at 2020 32 33 29 31 7.19% 2.21 [0.19, 25.64] Subtrobi (95%C) 155 113 58.0% 0.66 [0.30, 2.49] Total events 145 107 Heterogeneity: $Ch^2 = 0.72$, $df = 2 (P = 0.70)$; $I^2 = 0\%$ Text for overall effect: $Z = 0.28 (P = 0.78)$ 723 212 Heterogeneity: $Ch^2 = 1.16$, $df = 4 (P = 0.88)$; $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for subgroup differences : $Ch^2 = 0.17$, $df = 1 (P = 0.68)$, $I^2 = 0\%$ Text for overall effect : $Z = 0.06$ ($P = 0.06$) ; $I^2 = 6\%$ Text for overall effect : $Z = 0.06$ ($P = 0.06$) ; $I^2 = 6\%$ Text for overall effect : $Z = 0.06$ ($P = 0.06$) ; $I^2 = 6\%$ Text for overall effect : $Z = 0.71 (P < 0.0001)$ Text for overall effect : $Z = 0.71 (P < 0.0001)$ Text for overall effect : $Z = 0.06$ ($P = 0.06$); $I^2 = 6\%$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text for overall effect : $Z = 7.65 (P < 0.0001)$ Text (95%C) 24 27 10.0% 17.20 [13.88, 20.51]	Gu <i>et al.</i> 2020	45	48	44	46	22.0%		0.68	8 [0.11, 4.28] 🕇				
Subtoal (95%Cl) 155 113 58.0% $0.66 [0.30, 2.49]$ Total events 145 107 teterogeneity: $Ch^2 = 0.72$, $df = 2 (P = 0.78)$ Total (95%Cl) 290 224 100.0% $1.00 [0.46, 2.17]$ for versil effect: 2 = 0.28 (P = 0.78) Total (95%Cl) 290 224 100.0% $1.00 [0.46, 2.17]$ for versil effect: 2 = 0.08 (P = 0.68), $P = 0.06Test for versil effect: 2 = 0.02 (P = 0.78)Test for subgroup differences: Ch^2 = 0.17, df = 1 (P = 0.68), P = 0.06Test for subgroup differences: Ch^2 = 0.17, df = 1 (P = 0.68), P = 0.06Test for subgroup differences: Ch^2 = 0.17, df = 1 (P = 0.68), P = 0.06Total Vergentity: Ch^2 = 0.06 (N_p, Freed, 95%Cl ($	-luang <i>et al</i> . 2020	68	74	34	36	29.0%		0.67	r [0.13, 3.48] 🕇				
Total events 145 107 Heterogeneity: $Ch^2 = 0.72$, $df = 2$ ($P = 0.70$); $f^2 = 0\%$ Test for overall effect: $Z = 0.28$ ($P = 0.70$); $f^2 = 0\%$ Test for overall effect: $Z = 0.08$ ($P = 0.88$); $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup difference is : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup difference is : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup difference is : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for subgroup difference is : $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $f^2 = 0\%$ Test for overall effect : $Z = 2.67$ ($P = 0.06$); $f^2 = 66\%$ Test for overall effect : $Z = 6.71$ ($P < 0.060$); $f^2 = 66\%$ Test for overall effect : $Z = 6.71$ ($P < 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$); $f^2 = 65\%$ Test for overall effect : $Z = 7.57$, $df = 2$ ($P = 0.06$	Nabi <i>et al.</i> 2020	32	33	29	31	7.10%		2.21	[0.19, 25.64]				
Heterogenety: $Chi^2 = 0.72$, $df = 2$ ($P = 0.70$); $l^2 = 0\%$ Test for overall effect: $Z = 0.28$ ($P = 0.70$) Total (95%Cl) 290 224 100.0% 1.00 [0.46, 2.17] 1.00 [0.46, 2.1, 2.1] 1.00 [0.	Subtotal (95%Cl)		155		113	58.0%		0.86	5 [0.30, 2.49]				
Test for overall effect : $Z = 0.28$ ($P = 0.78$) Total events 273 212 Heterogeneity: $Ch^2 = 1.16$, $df = 4$ ($P = 0.88$); $I^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$. $df = 1$ ($P = 0.68$), $I^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$. $df = 1$ ($P = 0.68$), $I^2 = 0\%$ Test for subgroup differences : $Ch^2 = 0.17$. $df = 1$ ($P = 0.68$), $I^2 = 0\%$ Test for subgroup $\frac{M_{BA}}{SD}$ $\frac{SD}{Total}$ $\frac{M_{BA}}{M_{BA}}$ $\frac{SD}{SD}$ $\frac{Total}{Total}$ $\frac{M_{BA}}{M_{BA}}$ $\frac{SD}{N}$ $\frac{M_{BA}}{SD}$ $\frac{M_{BA}}{N}$ $M_{$	Total events	145		107									
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	leterogeneity : Chi ² = 0.72 , d	if = 2 (<i>P</i> = 0	0.70) ; / ² =	0%									
Total events 273 212 Heterogeneity: $Ch^2 = 1.16$, $df = 4$ ($P = 0.88$); $I^2 = 0\%$ Test for overall effect: $Z = 0.00$ ($P = 1.00$) Test for subgroup differences: $Ch^2 = 0.17$, $df = 1$ ($P = 0.68$). $I^2 = 0\%$ Total Mean SD Total Mean SD Total Mean Difference tudy or Subgroup Mean SD Total Mean SD Total Weight N, Fixed, 95%CL 1.1 Abstract amiliari <i>et al.</i> 2016 Abstract 59.2 16.7 23 47.7 13.2 26 15.20% 11.50 [3.00, 20.00] iao <i>et al.</i> 2016 Abstract 68.5 23.2 59 44.2 16.3 38 17.70% 24.30 [16.43, 32.17] ubtotal (95%Cl) 135 111 46.0% 16.72 [11.84,21.60] Heterogeneity: $Ch^2 = 5.83$, $df = 2$ ($P = 0.05$); $I^2 = 66\%$ est for overall effect: $Z = 6.71$ ($P < 0.00001$) Z Full-text is <i>et al.</i> 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] Huang <i>et al.</i> 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [18.46, 38.34] ubtotal (95%Cl) 159 116 54.0% 17.61 [13.10, 22.11] \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet \bullet	Test for overall effect : Z = 0.2	28 (<i>P</i> = 0.78	;)										
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Fotal (95%Cl)		290		224	100.0%		1.00	0 [0.46, 2.17]				
Test for overall effect : $Z = 0.00 (P = 1.00)$ Fest for subgroup differences : Ch ² = 0.17. df = 1 (P = 0.68) . $I^2 = 0\%$ Long Short Long Short Lang Short	Fotal events	273		212									
Under the subgroup difference: $Ch^2 = 0.77$. $df = 1 (P = 0.68)$. $I^2 = 0\%$ Long Short Mean Difference Not Nudy or Subgroup Mean SD Total Mean SD Total Mean Difference Not Mean Difference New Officience Mean Difference New Officience New Officience Total Mean Difference New Officience New Officience <td>Heterogeneity: Chi² = 1.16 , df</td> <td>f = 4 (<i>P</i> = 0</td> <td>.88); I2 =</td> <td>0%</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Heterogeneity: Chi ² = 1.16 , df	f = 4 (<i>P</i> = 0	.88); I2 =	0%									
Long Short Mean Difference Noted Short Mean Difference Mean Difference Mean Difference Noted Short Mean Difference Mean Difference Noted Short Mean Difference Mean Difference Noted Short Aldry or Subgroup Mean Difference Noted, 95%CI Long Short Mean Difference Noted, 95%CI Long Short Mean Difference Noted, 95%CI Aldry of Subgroup Mean Difference Noted, 95%CI Short Short Mean Difference Noted, 95%CI Short Short	Test for overall effect : Z = 0.0	00 (<i>P</i> = 1.00)							0.2	0.5 1	2	5
Long Short Mean Difference Mean Difference Mean Difference Neman Diference Nem	Test for subgroup differences :	: Chi ² = 0.17	. df = 1 (<i>P</i>	= 0.68) . 1	² = 0%					012			
Kudy or Subgroup Mean SD Total Mean SD Total Weight TV, Fixed, 95%Cl TV, Fixed, 95%Cl 1.1 Abstract 1.1 Abstract 59.2 16.7 2.3 47.7 13.2 2.6 15.20% 11.50 [3.00, 20.00] 5ao et al. 2017 Abstract 63.13 26.5 53 50.62 20.02 47 13.10% 12.51 [3.36, 21.66] 5ong et al. 2017 Abstract 68.5 23.2 59 44.2 16.3 38 17.70% 24.30 [16.43, 32.17] Subtotal (95%Cl) 135 111 46.0% 16.72 [11.84, 21.60] 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] 44.02 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] 44.02 45.6 18.5 36 15.80% 15.50 [7.16, 23.84] 45.6 16.2 48 31.7 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] 45.6 18.5 36 15.80% 17.61 [$13.10, 22.11$] 45.6 <td></td> <td>Lo</td> <td>ng</td> <td></td> <td>:</td> <td>Short</td> <td></td> <td></td> <td>N D:"</td> <td></td> <td>-</td> <td>Shore</td> <td></td>		Lo	ng		:	Short			N D:"		-	Shore	
Hamiliari et al. 2016 Abstract 59.2 16.7 23 47.7 13.2 26 15.20% 11.50 [3.00 , 20.00] Sao et al. 2017 Abstract 63.13 26.5 53 50.62 20.02 47 13.10% 12.51 [3.36 , 21.66] Song et al. 2016 Abstract 68.5 23.2 59 44.2 16.3 38 17.70% 24.30 [16.43 , 32.17] Subtotal (95%C1) 135 111 46.0% 16.72 [$11.84, 21.60$] 41.20 16.72 11.50 [$3.00, 20.07$] L2 Full-text 135 111 46.0% 16.72 [$11.84, 21.60$] 41.2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [$8.03, 20.77$] Labi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Labi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] 4.03 13.78 34 11.10% 28.40 [$13.86, 20.51$	itudy or Subgroup		-	Total	Mean	SD	Total	Weight					
$\begin{array}{c} 12 \\ 13 \\ 13 \\ 13 \\ 13 \\ 13 \\ 13 \\ 13 \\$.1 Abstract											-	
toong et al. 2016 Abstract 68.5 23.2 59 44.2 16.3 38 17.70% 24.30 [16.43, 32.17] ubtotal (95%Cl) 135 111 46.0% 16.72 [11.84,21.60] leterogeneity: $Chi^2 = 5.83$, $df = 2 (P = 0.05)$; $I^2 = 66\%$ test for overall effect: $Z = 6.71$ ($P < 0.00001$) 2 Full-text ivu et al. 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [8.03, 20.77] lutang et al. 2020 62.1 25.2 74 46.6 18.5 36 15.80% 15.50 [7.16, 23.84] labie et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [18.46, 38.34] ubtotal (95%Cl) 159 116 54.0% 17.61 [13.10, 22.11] \bullet test for overall effect: $Z = 7.65$ ($P < 0.0001$) 294 227 100.0% 17.20 [13.88, 20.51] \bullet	amiliari <i>et al</i> . 2016 Abstract	59.2	16.7	23	47.7	13.2	26	15.20%	11.50 [3.00, 20.0	00]			
ubtotal (95%Cl) 135 111 46.0% 16.72 [11.84,21.60] eterogeneity : Chi ² = 5.83 , df = 2 (P = 0.05) ; I^2 = 66% est for overall effect : Z = 6.71 (P < 0.00001)	ao <i>et al.</i> 2017 Abstract	63.13	26.5	53	50.62	20.02	47	13.10%	12.51 [3.36, 21.0	56]	-		
$\begin{array}{c} \text{Let rogeneity : } Ch^2 = 5.83 \text{, } df = 2 \ (P = 0.05 \) \text{; } I^2 = 66\% \\ \text{iest for overall effect : } Z = 6.71 \ (P < 0.00001 \) \\ \hline \\ \text{.2 Full-text} \\ \text{Su et al. } 2020 & 45.6 & 16.2 & 48 & 31.2 & 15.3 & 46 & 27.10\% & 14.40 \ [8.03, 20.77 \] \\ \text{Ituang et al. } 2020 & 62.1 & 25.2 & 74 & 46.6 & 18.5 & 36 & 15.80\% & 15.50 \ [7.16, 23.84 \] \\ \text{Itabi et al. } 2020 & 72.43 & 27.28 & 37 & 44.03 & 13.78 & 34 & 11.10\% & 28.40 \ [18.46, 38.34 \] \\ \text{Subtotal } (95\%\text{Cl}) & 159 & 116 & 54.0\% & 17.61 \ [13.10, 22.11 \] \\ \text{Heterogeneity : } Ch^2 = 5.75 \text{, } df = 2 \ (P = 0.06 \) \text{; } I^2 = 65\% \\ \text{iest for overall effect : } Z = 7.65 \ (P < 0.00001 \) \\ \text{Total } (95\%\text{Cl}) & 294 & 227 & 100.0\% & 17.20 \ [13.88, 20.51 \] \end{array}$	iong <i>et al</i> . 2016 Abstract	68.5	23.2	59	44.2	16.3	38	17.70%	24.30 [16.43, 32.	17]		_	
iest for overall effect : Z = 6.71 ($P < 0.0001$) 2 Full-text Gu et al. 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [$8.03, 20.77$] Auang et al. 2020 62.1 25.2 74 46.6 18.5 36 15.80% 15.50 [$7.16, 23.84$] Iabi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Iabi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Ieterogeneity : Chi ² = 5.75, df = 2 ($P = 0.06$); $I^{2} = 65\%$ 156 17.61 [$13.10, 22.11$] \bullet Total (95%Cl) 294 227 100.0% 17.20 [$13.88, 20.51$] \bullet	ubtotal (95%Cl)			135			111	46.0%	16.72 [11.84,21.	60]			
iest for overall effect : Z = 6.71 ($P < 0.0001$) 2 Full-text Gu et al. 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [$8.03, 20.77$] Auang et al. 2020 62.1 25.2 74 46.6 18.5 36 15.80% 15.50 [$7.16, 23.84$] Iabi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Iabi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Ieterogeneity : Chi ² = 5.75, df = 2 ($P = 0.06$); $I^{2} = 65\%$ 156 17.61 [$13.10, 22.11$] \bullet Total (95%Cl) 294 227 100.0% 17.20 [$13.88, 20.51$] \bullet	leterogeneity : Chi ² = 5.83 , di	f = 2 (P = 0.	05); I ² =	56%									
Gu et al. 2020 45.6 16.2 48 31.2 15.3 46 27.10% 14.40 [$8.03, 20.77$] Huang et al. 2020 62.1 25.2 74 46.6 18.5 36 15.80% 15.50 [$7.16, 23.84$] Habi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [$18.46, 38.34$] Hubtotal (95% Cl) 159 116 54.0% 17.61 [$13.10, 22.11$] \bullet Heterogeneity : $Chi^2 = 5.75$, $df = 2$ ($P = 0.06$); $I^2 = 65\%$ $I^2 = 65\%$ $I^2 = 7.65$ ($P < 0.00001$) $I^2 = 65\%$ $I^2 = 7.65$ ($P < 0.00001$) $I^2 = 65\%$ $I^2 = 0.06$ ($I^2 = 0.000$) $I^2 = 0.000$ ($I^2 = 0.000$) $I^2 = 0.000$ ($I^2 = 0.000$) $I^2 = 0.000$ ($I^2 = 0.0000$) $I^2 = 0.0000$ ($I^2 = 0.0000$) $I^2 = 0.0000$ ($I^2 = 0.0000$) $I^2 = 0.00000$ ($I^2 = 0.00000$) $I^2 = 0.00000$ ($I^2 = 0.00000$) $I^2 = 0.000000$ ($I^2 = 0.000000$) $I^2 = 0.0000000000000000000000000000000000$													
Huang et al. 2020 62.1 25.2 74 46.6 18.5 36 15.80% 15.50 $[7.16, 23.84]$ Habi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 $[18.46, 38.34]$ Subtotal (95%Cl) 159 116 54.0% 17.61 $[13.10, 22.11]$ Heterogeneity : $Chi^2 = 5.75$, $df = 2$ ($P = 0.06$); $I^2 = 65\%$ Image: Chi^2 = 5.75 (P < 0.00001)	2.2 Full-text												
Nabi et al. 2020 72.43 27.28 37 44.03 13.78 34 11.10% 28.40 [18.46, 38.34] Subtotal (95%Cl) 159 116 54.0% 17.61 [13.10, 22.11] Heterogeneity : Chi ² = 5.75 , df = 2 ($P = 0.06$) ; $I^2 = 65\%$ Fest for overall effect : Z = 7.65 ($P < 0.00001$) Total (95%Cl) 294 227 100.0% 17.20 [13.88, 20.51]	iu <i>et al</i> . 2020	45.6	16.2	48	31.2	15.3	46	27.10%	14.40 [8.03, 20.3	77]			
ubtotal (95%Cl) 159 116 54.0% 17.61 [13.10, 22.11] leterogeneity : Chi ² = 5.75 , df = 2 (P = 0.06) ; I ² = 65% est for overall effect : Z = 7.65 (P < 0.00001)	luang <i>et al.</i> 2020	62.1	25.2	74	46.6	18.5	36	15.80%	15.50 [7.16, 23.8	34]	<u> </u>		
deterogeneity : Chi ² = 5.75 , df = 2 (P = 0.06) ; I ² = 65% est for overall effect : Z = 7.65 (P < 0.00001)	abi <i>et al</i> . 2020	72.43	27.28	37	44.03	13.78	34	11.10%	28.40 [18.46, 38.	34]			
Heterogeneity : $Chi^2 = 5.75$, $df = 2 (P = 0.06)$; $I^2 = 65\%$ iest for overall effect : $Z = 7.65 (P < 0.00001)$ Total (95%Cl) 294 227 100.0% 17.20 [13.88, 20.51]	ubtotal (95%Cl)			159			116	54.0%			.		
est for overall effect : Z = 7.65 (P < 0.00001)		f = 2 (<i>P</i> = 0	.06); I ² =						_ ,	-		-	
		•											
	Total (95%Cl)			294			227	100.0%	17.20 [13.88. 20	51]			
		df - 5 (<i>p</i> -	0 04) • 72 -				,	200.075				━_	

Test for overall effect : Z= 10.17 ($\it P < 0.00001$)

Test for subgroup differences : Chi² = 0.07. df = 1 (P = 0.79) . $I^2 = 0\%$



10

Short

20

-20

-10

Long


Figure 4 Operative time of long vs short myotomy.

guidelines of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), for cases of achalasia, esophageal myotomy length should be ≥ 4 cm and the gastromyotomy length should be 1-2 cm[31]. Therefore, it was hypothesized that a modified POEM procedure with a LM might be as effective as the LM procedure in achalasia treatment as it ensured sufficient LES cutting while ameliorating complications and decreasing operation time. To test this hypothesis, Wang et al[10] enrolled 46 patients who underwent modified POEM with shorter submucosal tunnel (average length



Raisbideng® WJGS | https://www.wjgnet.com

Α	Lo	ng		Short			
Study or Subgroup	Events Total		Events Total		Weight	Odds Ratio M-H, Fixed, 95%CI	Odds Ratio M-H, Fixed, 95%Cl
3.1 Abstract							
Familiari <i>et al</i> . 2016 Abstract.	10	23	17	26	27.0%	0.41 [0.13, 1.29] 🗲	• • • • • • • • • • • • • • • • • • • •
Gao <i>et al</i> . 2017 Abstract.	6	53	6	47	16.90%	0.87 [0.26, 2.92] 🗲	
Gong <i>et al</i> . 2016 Abstract.	11	59	6	38	17.80%	1.22 [0.41, 3.64]	
Subtotal (95%Cl)		135		111	61.70%	0.77 [0.40, 1.47]	
Total events	27		29				
Heterogeneity : Chi ² = 1.90 , df	= 2 (<i>P</i> = 0	.39); /2=	0%				
Test for overall effect : $Z = 0.79$	9 (<i>P</i> = 0.43)					
3.2 Full text							
Gu <i>et al</i> . 2020	7	48	4	46	10.40%	1.79 [0.49, 6.59]	
Huang <i>et al</i> . 2020	11	74	3	36	10.30%	1.92 [0.50, 7.37]	
Nabi <i>et al.</i> 2020	18	37	11	34	17.60%	1.98 [0.75, 5.20]	_ • • •
Subtotal (95% Cl)		159		116	38.30%	1.91 [0.98, 3.75]	
Total events	36		18				
Heterogeneity : $Chi^2 = 0.01$, df	= 2 (<i>P</i> = 0.	99);/²=	0%				
Test for overall effect : Z= 1.89	(<i>P</i> = 0.06)						
Total (95%Cl)		294		227	100.0%	1.21 [0.76, 1.91]	
Total events	63		47				
Heterogeneity : $Chi^2 = 5.51$, df	= 5 (P = 0	.36); /2=	9%				
Test for overall effect : $Z = 0.83$	L (<i>P</i> = 0.42)					0.5 0.7 1 1.5 2
Test for subgroup differences :	ChI ² = 3.65.	df = 1 (<i>P</i>	e = 0.06) . <i>I</i>	² = 72.6%			Long Short
В	Long		Short		٩	1ean Difference	Mean Difference



DOI: 10.4240/wjgs.v14.i3.247 **Copyright** The Author(s) 2022.



Saishideng® WJGS | https://www.wjgnet.com






Figure 5 Long vs short myotomy. Meta-analysis of secondary outcomes. A: Endoscopic reflux esophagitis; B: Hospitalization; C: Major bleeding.

6.8 cm) and endoscopic myotomy of muscle bundles (total average length 5.4 cm). They reported that modified POEM with LM showed great safety and commendable short-term efficacy in treating achalasia. However, for patients with type I and II achalasia, a short esophageal myotomy may be sufficient[10].

The present analysis, which was based on RCTs and a retrospective study, confirmed that POEM offered excellent efficacy with a high clinical success rate. The treatment efficacy was similar between the SM and LM procedures, regardless of the definition used, length of myotomy, publication type and the statistical method employed to pool the data. The meta-analysis of manometric outcomes, where no significant disparities were detected, further endorsed the lack of clinical differences between LM and SM.

Another matter of debate is GERD after POEM[32]. Several technical refinements have been attempted to decrease the odds of post-POEM GERD, including a selective myotomy of the inner circular muscle[33], endoscopic fundoplication[34], or limiting the length of gastromyotomy[35]. The proper location of the gastroesophageal junction (GEJ) is critical in ensuring the procedure's effect-iveness and may have an impact on GERD[36,37]. Many reports showed a lower GERD incidence after POEM due to the preservation of the pharyngoesophageal ligament[38,39]. In the present meta-analysis, the incidence rate of GERD was similar between the SM and LM procedures.

Regarding POEM-related AEs, multicenter studies showed that the technique was associated with a low incidence of severe AEs (< 1%)[40,41]. Interestingly, we found that the total incidence rate of AEs, including hospitalization and major bleeding, were comparable between the two groups. Procedure-related outcomes were also evaluated. As expected from our clinical experience, the SM took much less time compared with the LM but the treatment effects were similar.

This meta-analysis had some limitations. First, the number of studies was very small and three RCTs were only retrieved as abstracts. Although we conducted subgroup analysis based on abstract and full-text, more studies were still needed to analyze the results. Second, only three articles evaluated IRP after POEM treatment. Third, a longer myotomy is thought to be more effective on controlling symptoms caused by the esophageal spasm of type III achalasia. However, in this meta-analysis, due to the small number of patients with type III achalasia and recent literature[18], our conclusions might not apply to type III achalasia treatment and a short myotomy could not be recommended. We expected more RCTs to examine the effect of shorter or longer in the treatment of type III achalasia. Due to the lack of relevant research articles, we did not evaluate the postoperative efficacy of POEM for achalasia subtypes. Fourth, the follow-up duration was relatively short so this study was unable to compare the long-term efficacy and AES between LM and SM procedures.

WJGS https://www.wjgnet.com

CONCLUSION

In conclusion, short myotomy has the advantage of reduced procedure time in the treatment of achalasia compared to long myotomy, but the clinical success rate, AEs, and reflux rate were comparable. Thus, peroral endoscopic shorter myotomy could have a great clinical application prospect. Our results are restricted by the small number of patients, short follow-up duration, and a lack of specific definition of short myotomy. Future studies with a larger sample size and longer follow-up duration are warranted to evaluate the long-term efficacy and safety of these two procedures in POEM.

ARTICLE HIGHLIGHTS

Research background

For a long time, peroral endoscopic myotomy (POEM) has been demonstrated to be safe and effective in the treatment of achalasia.

Research motivation

Longer myotomy is the standard POEM procedure for achalasia, but its effectiveness compared with shorter myotomy is not well known. Thus, we want to provide an analysis to assess the clinical outcomes of shorter and longer myotomy.

Research objectives

To conduct a meta-analysis to compare the clinical effectiveness of the two procedures.

Research methods

The PubMed, Web of Science, Cochrane Library, clinicaltrials.gov, and EMBASE databases were used to search for relevant studies to compare shorter and longer myotomy in POEM for achalasia treatment.

Research results

Longer and shorter myotomy groups in treating achalasia had similar excellent effectiveness. Shorter myotomy had significantly reduced mean operative time compared with the longer procedure. There were no statistically significant differences in AE's rates, including gastroesophageal reflux diseases, hospital stay and major bleeding between the two procedures.

Research conclusions

Short myotomy has the advantage of shorter procedure time in the treatment of achalasia compared to long myotomy, but the clinical success rate, adverse events , and reflux rate were comparable.

Research perspectives

Future randomized clinical trials should determine whether the benefits remain comparable after years of follow-up.

FOOTNOTES

Author contributions: Weng CY and He CH collected data; Zhuang MY analyzed the data and wrote the first draft of the manuscript; Xu JL and Lyu B were major contributors in editing the manuscript; All authors read and approved the final manuscript.

Supported by the National Natural Science Foundation of China, No. 8177030774.

Conflict-of-interest statement: The authors declare they have no competing financial and non-financial interests.

PRISMA 2009 Checklist statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China



WJGS | https://www.wjgnet.com

ORCID number: Chun-Yan Weng 0000-0003-3618-9629; Cheng-Hai He 0000-0001-8322-2669; Ming-Yang Zhuang 0000-0001-6392-716X; Jing-Li Xu 0000-0002-2264-8591; Bin Lyu 0000-0002-6247-571X.

S-Editor: Wang LL L-Editor: Filipodia P-Editor: Wu RR

REFERENCES

- 1 Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet 2014; 383: 83-93 [PMID: 23871090 DOI: 10.1016/s0140-6736(13)60651-0
- Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. ACG Clinical Guidelines: Diagnosis and Management of 2 Achalasia. Am J Gastroenterol 2020; 115: 1393-1411 [PMID: 32773454 DOI: 10.14309/ajg.00000000000731]
- 3 Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 2010; 42: 265-271 [PMID: 20354937 DOI: 10.1055/s-0029-1244080
- 4 Inoue H, Sato H, Ikeda H, Onimaru M, Sato C, Minami H, Yokomichi H, Kobayashi Y, Grimes KL, Kudo SE. Per-Oral Endoscopic Myotomy: A Series of 500 Patients. J Am Coll Surg 2015; 221: 256-264 [PMID: 26206634 DOI: 10.1016/j.jamcollsurg.2015.03.057]
- 5 Nabi Z, Ramchandani M, Chavan R, Kalapala R, Darisetty S, Rao GV, Reddy N. Per-oral endoscopic myotomy for achalasia cardia: outcomes in over 400 consecutive patients. Endosc Int Open 2017; 5: E331-E339 [PMID: 28484733 DOI: 10.1055/s-0043-1055171
- Youn YH, Minami H, Chiu PW, Park H. Peroral Endoscopic Myotomy for Treating Achalasia and Esophageal Motility 6 Disorders. J Neurogastroenterol Motil 2016; 22: 14-24 [PMID: 26717928 DOI: 10.5056/jnm15191]
- He C, Li M, Lu B, Ying X, Gao C, Wang S, Ma C, Jin C. Long-Term Efficacy of Peroral Endoscopic Myotomy for Patients with Achalasia: Outcomes with a Median Follow-Up of 36 mo. Dig Dis Sci 2019; 64: 803-810 [PMID: 30478767 DOI: 10.1007/s10620-018-5373-0]
- 8 Inoue H, Shiwaku H, Kobayashi Y, Chiu PWY, Hawes RH, Neuhaus H, Costamagna G, Stavropoulos SN, Fukami N, Seewald S, Onimaru M, Minami H, Tanaka S, Shimamura Y, Santi EG, Grimes K, Tajiri H. Statement for gastroesophageal reflux disease after peroral endoscopic myotomy from an international multicenter experience. Esophagus 2020; 17: 3-10 [PMID: 31559513 DOI: 10.1007/s10388-019-00689-6]
- 9 Grimes KL, Bechara R, Shimamura Y, Ikeda H, Inoue H. Gastric myotomy length affects severity but not rate of postprocedure reflux: 3-year follow-up of a prospective randomized controlled trial of double-scope per-oral endoscopic myotomy (POEM) for esophageal achalasia. Surg Endosc 2020; 34: 2963-2968 [PMID: 31463720 DOI: 10.1007/s00464-019-07079-0]
- 10 Wang J, Tan N, Xiao Y, Chen J, Chen B, Ma Z, Zhang D, Chen M, Cui Y. Safety and efficacy of the modified peroral endoscopic myotomy with shorter myotomy for achalasia patients: a prospective study. Dis Esophagus 2015; 28: 720-727 [PMID: 25214469 DOI: 10.1111/dote.12280]
- 11 Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 20 July 2021]. Available from: https://training.cochrane.org/handbook
- Nabi Z, Ramchandani M, Sayyed M, Chavan R, Darisetty S, Goud R, Murthy HVV, Reddy DN. Comparison of Short 12 Versus Long Esophageal Myotomy in Cases With Idiopathic Achalasia: A Randomized Controlled Trial. J Neurogastroenterol Motil 2021; 27: 63-70 [PMID: 32675389 DOI: 10.5056/jnm20022]
- Huang S, Ren Y, Peng W, Gao Q, Peng Y, Gong W, Tang X. Peroral endoscopic shorter versus longer myotomy for the 13 treatment of achalasia: a comparative retrospective study. Esophagus 2020; 17: 477-483 [PMID: 32361976 DOI: 10.1007/s10388-020-00739-4]
- Gu L, Ouyang Z, Lv L, Liang C, Zhu H, Liu D. Safety and efficacy of peroral endoscopic myotomy with standard 14 myotomy versus short myotomy for treatment-naïve patients with type II achalasia: a prospective randomized trial. Gastrointest Endosc 2021; 93: 1304-1312 [PMID: 33058884 DOI: 10.1016/j.gie.2020.10.006]
- Familiari Pietro, Anna Cali, Rosario Landi, Giovanni Gigante, Ivo Boskoski, Federico Barbaro, Andrea Tringali, Santiago 15 Andrade Zurita, Vincenzo Perri, Guido Costamagna. Long vs Short POEM for the Treatment of Achalasia. Interim Analysis of a Randomized Controlled Trial. Gastrointestinal Endoscopy 2016; 83
- 16 Gao QP, Tu SF, Tang XW, Huang SL, Gong W. Mid-term Outcomes of a Single Center Randomized Controlled Trial Comparing Peroral Endoscopic Short versus Long Myotomy for Achalasia in China. The American Journal of Gastroenterology
- Gong W, Tang XW, Huang SL, Ren YT, Gao QP, Zhou JQ, Zhang XF, Bo Jiang. Peroral Endoscopic Shorter versus 17 Longer Myotomy for the Treatment of Achalasia: A Comparative Study. The American Journal of Gastroenterology
- Kumbhari V, Tieu AH, Onimaru M, El Zein MH, Teitelbaum EN, Ujiki MB, Gitelis ME, Modayil RJ, Hungness ES, Stavropoulos SN, Shiwaku H, Kunda R, Chiu P, Saxena P, Messallam AA, Inoue H, Khashab MA. Peroral endoscopic myotomy (POEM) vs laparoscopic Heller myotomy (LHM) for the treatment of Type III achalasia in 75 patients: a multicenter comparative study. Endosc Int Open 2015; 3: E195-E201 [PMID: 26171430 DOI: 10.1055/s-0034-1391668]
- 19 Ortega JA, Madureri V, Perez L. Endoscopic myotomy in the treatment of achalasia. Gastrointest Endosc 1980; 26: 8-10 [PMID: 7358270 DOI: 10.1016/s0016-5107(80)73249-2]
- 20 Pasricha PJ, Hawari R, Ahmed I, Chen J, Cotton PB, Hawes RH, Kalloo AN, Kantsevoy SV, Gostout CJ. Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy 2007; 39: 761-764 [PMID: 17703382 DOI: 10.1055/s-2007-966764]



- 21 Inoue H, Santi EG, Onimaru M, Kudo SE. Submucosal endoscopy: from ESD to POEM and beyond. *Gastrointest Endosc Clin N Am* 2014; 24: 257-264 [PMID: 24679236 DOI: 10.1016/j.giec.2013.12.003]
- 22 NOSCAR POEM White Paper Committee., Stavropoulos SN, Desilets DJ, Fuchs KH, Gostout CJ, Haber G, Inoue H, Kochman ML, Modayil R, Savides T, Scott DJ, Swanstrom LL, Vassiliou MC. Per-oral endoscopic myotomy white paper summary. *Gastrointest Endosc* 2014; 80: 1-15 [PMID: 24950639 DOI: 10.1016/j.gie.2014.04.014]
- 23 Cho YK, Kim SH. Current Status of Peroral Endoscopic Myotomy. *Clin Endosc* 2018; **51**: 13-18 [PMID: 29397656 DOI: 10.5946/ce.2017.165]
- 24 Ponds FA, Fockens P, Lei A, Neuhaus H, Beyna T, Kandler J, Frieling T, Chiu PWY, Wu JCY, Wong VWY, Costamagna G, Familiari P, Kahrilas PJ, Pandolfino JE, Smout AJPM, Bredenoord AJ. Effect of Peroral Endoscopic Myotomy vs Pneumatic Dilation on Symptom Severity and Treatment Outcomes Among Treatment-Naive Patients With Achalasia: A Randomized Clinical Trial. *JAMA* 2019; 322: 134-144 [PMID: 31287522 DOI: 10.1001/jama.2019.8859]
- 25 Kahrilas PJ, Katzka D, Richter JE. Clinical Practice Update: The Use of Per-Oral Endoscopic Myotomy in Achalasia: Expert Review and Best Practice Advice From the AGA Institute. *Gastroenterology* 2017; 153: 1205-1211 [PMID: 28989059 DOI: 10.1053/j.gastro.2017.10.001]
- 26 von Renteln D, Inoue H, Minami H, Werner YB, Pace A, Kersten JF, Much CC, Schachschal G, Mann O, Keller J, Fuchs KH, Rösch T. Peroral endoscopic myotomy for the treatment of achalasia: a prospective single center study. *Am J Gastroenterol* 2012; **107**: 411-417 [PMID: 22068665 DOI: 10.1038/ajg.2011.388]
- 27 Costamagna G, Marchese M, Familiari P, Tringali A, Inoue H, Perri V. Peroral endoscopic myotomy (POEM) for oesophageal achalasia: preliminary results in humans. *Dig Liver Dis* 2012; 44: 827-832 [PMID: 22609465 DOI: 10.1016/j.dld.2012.04.003]
- 28 Chiu PW, Wu JC, Teoh AY, Chan Y, Wong SK, Liu SY, Yung MY, Lam CC, Sung JJ, Chan FK, Lau JY, Ng EK. Peroral endoscopic myotomy for treatment of achalasia: from bench to bedside (with video). *Gastrointest Endosc* 2013; 77: 29-38 [PMID: 23043852 DOI: 10.1016/j.gie.2012.08.018]
- 29 Minami H, Isomoto H, Yamaguchi N, Matsushima K, Akazawa Y, Ohnita K, Takeshima F, Inoue H, Nakao K. Peroral endoscopic myotomy for esophageal achalasia: clinical impact of 28 cases. *Dig Endosc* 2014; 26: 43-51 [PMID: 23581563 DOI: 10.1111/den.12086]
- 30 Shi Y, Xiao Y, Peng S, Lin J, Xiong L, Chen M. Normative data of high-resolution impedance manometry in the Chinese population. J Gastroenterol Hepatol 2013; 28: 1611-1615 [PMID: 23730912 DOI: 10.1111/jgh.12285]
- 31 Stefanidis D, Richardson W, Farrell TM, Kohn GP, Augenstein V, Fanelli RD; Society of American Gastrointestinal and Endoscopic Surgeons. SAGES guidelines for the surgical treatment of esophageal achalasia. *Surg Endosc* 2012; 26: 296-311 [PMID: 22044977 DOI: 10.1007/s00464-011-2017-2]
- 32 Rösch T, Repici A, Boeckxstaens G. Will Reflux Kill POEM? *Endoscopy* 2017; **49**: 625-628 [PMID: 28658688 DOI: 10.1055/s-0043-112490]
- 33 Wang XH, Tan YY, Zhu HY, Li CJ, Liu DL. Full-thickness myotomy is associated with higher rate of postoperative gastroesophageal reflux disease. *World J Gastroenterol* 2016; 22: 9419-9426 [PMID: 27895430 DOI: 10.3748/wjg.v22.i42.9419]
- 34 Tyberg A, Choi A, Gaidhane M, Kahaleh M. Transoral incisional fundoplication for reflux after peroral endoscopic myotomy: a crucial addition to our arsenal. *Endosc Int Open* 2018; 6: E549-E552 [PMID: 29756011 DOI: 10.1055/a-0584-6802]
- 35 Inoue H, Shiwaku H, Iwakiri K, Onimaru M, Kobayashi Y, Minami H, Sato H, Kitano S, Iwakiri R, Omura N, Murakami K, Fukami N, Fujimoto K, Tajiri H. Clinical practice guidelines for peroral endoscopic myotomy. *Dig Endosc* 2018; 30: 563-579 [PMID: 30022514 DOI: 10.1111/den.13239]
- 36 Teitelbaum EN, Sternbach JM, El Khoury R, Soper NJ, Pandolfino JE, Kahrilas PJ, Lin Z, Hungness ES. The effect of incremental distal gastric myotomy lengths on EGJ distensibility during POEM for achalasia. *Surg Endosc* 2016; 30: 745-750 [PMID: 26092005 DOI: 10.1007/s00464-015-4269-8]
- 37 Teitelbaum EN, Soper NJ, Pandolfino JE, Kahrilas PJ, Hirano I, Boris L, Nicodème F, Lin Z, Hungness ES. Esophagogastric junction distensibility measurements during Heller myotomy and POEM for achalasia predict postoperative symptomatic outcomes. *Surg Endosc* 2015; 29: 522-528 [PMID: 25055891 DOI: 10.1007/s00464-014-3733-1]
- 38 Awaiz A, Yunus RM, Khan S, Memon B, Memon MA. Systematic Review and Meta-Analysis of Perioperative Outcomes of Peroral Endoscopic Myotomy (POEM) and Laparoscopic Heller Myotomy (LHM) for Achalasia. Surg Laparosc Endosc Percutan Tech 2017; 27: 123-131 [PMID: 28472017 DOI: 10.1097/sle.00000000000402]
- 39 Schneider AM, Louie BE, Warren HF, Farivar AS, Schembre DB, Aye RW. A Matched Comparison of Per Oral Endoscopic Myotomy to Laparoscopic Heller Myotomy in the Treatment of Achalasia. J Gastrointest Surg 2016; 20: 1789-1796 [PMID: 27514392 DOI: 10.1007/s11605-016-3232-x]
- 40 Haito-Chavez Y, Inoue H, Beard KW, Draganov PV, Ujiki M, Rahden BHA, Desai PN, Pioche M, Hayee B, Haji A, Saxena P, Reavis K, Onimaru M, Balassone V, Nakamura J, Hata Y, Yang D, Pannu D, Abbas A, Perbtani YB, Patel LY, Filser J, Roman S, Rivory J, Mion F, Ponchon T, Perretta S, Wong V, Maselli R, Ngamruengphong S, Chen YI, Bukhari M, Hajiyeva G, Ismail A, Pieratti R, Kumbhari V, Galdos-Cardenas G, Repici A, Khashab MA. Comprehensive Analysis of Adverse Events Associated With Per Oral Endoscopic Myotomy in 1826 Patients: An International Multicenter Study. *Am J Gastroenterol* 2017; **112**: 1267-1276 [PMID: 28534521 DOI: 10.1038/ajg.2017.139]
- 41 Werner YB, von Renteln D, Noder T, Schachschal G, Denzer UW, Groth S, Nast JF, Kersten JF, Petzoldt M, Adam G, Mann O, Repici A, Hassan C, Rösch T. Early adverse events of per-oral endoscopic myotomy. *Gastrointest Endosc* 2017; 85: 708-718.e2 [PMID: 27609778 DOI: 10.1016/j.gie.2016.08.033]

Raisbideng® WJGS | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

